AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 218.13B |
| Revenue (ttm) | 48.11B |
| Net Income (ttm) | 7.06B |
| Shares Out | n/a |
| EPS (ttm) | 4.52 |
| PE Ratio | 30.88 |
| Forward PE | 16.77 |
| Dividend | 2.91 (2.13%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 6,456 |
| Average Volume | 9,799 |
| Open | 136.90 |
| Previous Close | 137.55 |
| Day's Range | 136.45 - 138.10 |
| 52-Week Range | 111.00 - 158.20 |
| Beta | n/a |
| RSI | 70.14 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit Therapeutics Inc (NASDAQ: SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small ...
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs p...
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMis...
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca
FibroGen (FGEN) gains over 3% after China approves its sale to AstraZeneca Treasury. Deal set to close by Q3 2025.
Scared of needles? AstraZeneca launches FluMist Home nasal spray delivery
AstraZeneca introduces FluMist Home, offering a needle-free flu vaccine delivered directly to your door. This FDA-approved nasal spray allows adults aged 18-49 and parents of children aged 2-17 to adm...
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine appr...
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery
AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca t...
George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98%
George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98%
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients . The initiative , announced Tuesday, combines governme...
AstraZeneca: Great Portfolio, But Not A Great Price
Melrose boss soars to top of the Footsie pay league
Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the relatively unknown Dilnot.
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG)
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON , Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani Medical Inc. (NASDAQ: VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's propriet...
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a...
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval
Primary focus on pancreatic cancer Mid-year report of Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs ...
Top global stories this week: HSBC, AstraZeneca, Nissan among notable names
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Trump demands U.S. drug price cuts, pharma shares slump
AstraZeneca Plc fell as much as 4.2%, and GSK Plc dropped 2.1%
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Trump threatens NHS with higher drug prices
The US president has told GSK and AstraZeneca to ‘negotiate harder with foreign freeloading nations’
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...